Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides.

导出 OA

翻译打印收藏纠错

作者： Jennifer,Pfeil ^[1] ; Mario,Simonetti ^[2] ; Uta,Lauer ^[1] ; Bianca,von Thülen ^[3] ; Pawel,Durek ^[1] ; Christina,Poulsen ^[1] ; Justyna,Pawlowska ^[1] ; Matthias,Kröger ^[1] ; Ralf,Krähmer ^[3] ; Frank,Leenders ^[3] ; Ute,Hoffmann ^[1] ; Alf,Hamann ^[4]

作者单位： Experimental Rheumatology, Deutsches Rheuma-Forschungszentrum, a Leibniz-Institute, Berlin, Germany. ^[1] Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin, Berlin, Germany. ^[2] Celares GmbH, Berlin, Germany. ^[3] Experimental Rheumatology, Deutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, Berlin 10117, Germany. ^[4]

关键词 allergy autoimmunity chronic autoimmune disease drug delivery experimental autoimmune encephalomyelitis multiple sclerosis peptide vaccination regulatory T cells specific immunotherapy (SIT)therapy tolerance induction

DOI 10.1177/20406223211037830

PMID 34408824

发布时间 2023-11-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Therapeutic advances in chronic disease

2021年12卷

20406223211037830页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides.

Therapeutic advances in chronic disease

相似文献

Therapeutic advances in chronic disease

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Prevention of EAE by tolerogenic vaccination with PEGylated antigenic peptides.

Therapeutic advances in chronic disease

相似文献

Therapeutic advances in chronic disease

相关期刊

检索历史清除